UPDATE : Wednesday, October 16, 2019
상단여백
Novo Nordisk's Ryzodeg leads Korean mixed insulin market by Lee Han-soo 2019-09-09 14:18
PARP inhibitors to show intense rivalry at ESMO 2019 by Kim Yun-mi 2019-09-09 11:56
Ildong to sell GSK’s influenza treatment by Lee Han-soo 2019-09-06 17:02
Yuhan to expand biz scope to central nervous system disease by Jeong Sae-im 2019-09-06 14:56
Seoul Pharmaceutical to export erectile dysfunction treatment to Taiwan by Lee Han-soo 2019-09-05 17:04
라인
Lilly’s migraine treatment Emgality lands in Korea by Lee Hye-seon 2019-09-05 16:24
Daewoong, Medytox squabble over appraisal of additional spore for Nabota by Lee Han-soo 2019-09-05 14:35
[News analysis] Takeda Korea’s merger with Shire has to surmount big hurdle; labor union by Lee Han-soo 2019-09-04 17:06
JW Pharmaceutical acquires Vietnamese drugmaker by Lee Han-soo 2019-09-04 15:16
Takeda Korea vows to release 16 new drugs by 2023 by Kim Yun-mi 2019-09-03 15:40
라인
SK goes global by developing new drugs, conducting CDMO biz by Jeong Sae-im 2019-09-03 14:58
Hanmi, Daewoong among 20 innovative top-tier drugmakers in Asia Pacific by Jeong Sae-im 2019-09-02 17:33
Antidiabetic Forxiga proves efficacy in heart failure by Kim Yun-mi 2019-09-02 11:35
Daewoong, Medytox differ in interpreting spore appraisal for Nabota by Lee Han-soo 2019-08-30 16:26
Atopic dermatitis patients fall in despair as Dupixent may not get coverage soon by Kim Yun-mi 2019-08-30 16:26
라인
Doctors seem less eager to participate in ‘No-Japan’ campaign. Why? by Lee Han-soo 2019-08-30 15:58
JW Pharmaceutical’s hyperlipidemia drug Livalo safe from diabetes risk by Jeong Sae-im 2019-08-30 14:49
'Mucosa healing essential for treating inflammatory bowel disease' by Lee Han-soo 2019-08-30 12:42
CAR-T therapy Kymriah, pie in the sky for Korean patients by Kim Yun-mi 2019-08-29 14:35
Ildong’s subsidiary secures 1st anticancer drug pipeline by Lee Han-soo 2019-08-29 13:37
여백
여백
여백
Back to Top